摘要
目的探讨振源胶囊联合黛力新治疗冠心病合并焦虑抑郁患者的临床疗效及其对血清炎性因子的影响。方法选取2018年1月—2019年12月期间周口市中医院心血管内科收治的冠心病合并焦虑抑郁患者103例为研究对象,按照随机数字表法分治疗组患者52例,对照组患者51例。对照组口服黛力新胶囊,治疗组在对照组治疗基础上加服振源胶囊,治疗10周后比较分析两组患者①临床疗效;②治疗前后焦虑、抑郁情绪变化;③治疗前后心绞痛及心电图改善情况;④治疗前后中医症状积分;⑤治疗前后两组患者血清中白细胞介素6(interleukin6,IL-6),肿瘤坏死因子α(tumor necrosis factorα,TNF-α)以及C反应蛋白(C-reactive protein,CRP)水平变化;⑥不良反应。结果①治疗后治疗组临床有效率84.6%(44/52)显著高于对照组62.7%(32/51)(P<0.05)。②两组患者治疗后HAMA、HAMD评分与治疗前比较均显著下降(P<0.05);且治疗组患者治疗后HAMA、HAMD评分均显著低于对照组(P<0.05)。③治疗后治疗组心绞痛及心电图改善情况88.5%(46/52)显著高于对照组68.6%(35/51)(P<0.05)。④两组患者治疗后中医症状积分均显著低于治疗前(P<0.05);且治疗组患者治疗后中医症状积分均显著低于对照组(P<0.05)。⑤两组患者治疗后IL-6、TNF-α及CRP水平均显著低于治疗前(P<0.05);且治疗组患者治疗后IL-6、TNF-α及CRP水平均显著低于对照组(P<0.05)。⑥两组患者治疗期间均未出现心律失常,如心动过缓、室性早搏、房颤等;也未出现心衰、心梗,血压、血糖升高等副作用。结论振源胶囊联合黛力新治疗冠心病合并焦虑抑郁疗效显著,能够缓解患者焦虑抑郁状态,降低炎症反应,提高冠心病疗效,不良反应小。
Objective To explore the clinical efficacy of Zhenyuan Capsule combined with Deanxit in the treatment of patients with coronary heart disease combined with anxiety and depression and its effect on serum inflammatory factors.Method From January 2018 to December 2019,103 patients with coronary heart disease combined with anxiety and depression who were admitted to the Department of Cardiology,Zhoukou Hospital of Traditional Chinese Medicine were selected as the research objects.According to the random number table,52 patients in the treatment group and 51 patients in the control group were selected.example.The control group took Oral Dailixin capsules,and the treatment group added Zhenyuan capsules to the treatment of the control group.After 10 weeks of treatment,the two groups were compared and analyzed①Clinical efficacy;②Changes in anxiety and depression before and after treatment;③Angina pectoris and ECG before and after treatment To improve the situation;④TCM symptom score before and after treatment;⑤Interleukin 6(interleukin6,IL-6),tumor necrosis factorα(TNF-α)and C-reactive protein(C-reactive protein,CRP)level changes;⑥Adverse reactions.Results①After treatment,the clinical effective rate of the treatment group was 84.6%(44/52),which was significantly higher than that of the control group 62.7%(32/51).There were differences between the two groups Statistical significance(P<0.05).②The HAMA and HAMD scores of the two groups of patients after treatment were significantly decreased compared with those before the treatment,and the difference was statistically significant(P<0.05);and the HAMA and HAMD scores of the patients in the treatment group after treatment Both were significantly lower than the control group,and the difference between the two groups was statistically significant(P<0.05).③After treatment,the improvement of angina pectoris and electrocardiogram in the treatment group was 88.5%(46/52),which was significantly higher than the control group 68.6%(35/51),the difference between the two groups was statistically significant(P<0.05).④After treatment,the TCM symptom scores of the two groups were significantly lower than those before treatment,and the difference was statistically significant(P<0.05);The symptom scores were significantly lower than those of the control group,and the difference between the two groups was statistically significant(P<0.05).⑤The levels of IL-6,TNF-αand CRP after treatment in the two groups were significantly lower than before treatment,and the difference was statistically significant Significance(P<0.05);and the levels of IL-6,TNF-αand CRP in the treatment group were significantly lower than those in the control group after treatment,and the difference between the two groups was statistically significant(P<0.05).⑥During treatment of the two groups No arrhythmia,such as bradycardia,premature ventricular contractions,atrial fibrillation,etc.;no side effects such as heart failure,myocardial infarction,blood pressure,blood sugar increase,etc.Conclusion Zhenyuan capsule combined with Deanxit has clinical curative effect in the treatment of Coronary heart disease with anxiety and depression,significantly improve patients’anxiety and depression symptoms,reduce inflammatory response,improve the treatment effect of coronary heart disease,and has less adverse reactions to the heart.It is worthy of clinical application.
作者
史珍珍
王留伟
汤继海
张彦来
SHI Zhen-zhen;WANG Liu-wei;TANG Ji-hai;ZHANG Yan-lai(Department of Cardiology,Zhoukou Traditional Chinese Medicine Hospital,Zhoukou Henan 466000)
出处
《世界中西医结合杂志》
2021年第1期153-156,161,共5页
World Journal of Integrated Traditional and Western Medicine
基金
河南省中医药科学研究专项课题(2018ZY3038)。
关键词
冠心病
焦虑抑郁
炎症因子
振源胶囊
黛力新
Coronary Heart Disease
Anxiety and Depression
Inflammatory Factor
Zhenyuan Capsule
Deanxit
